- Home
- KNOP vs OABI Comparison
KNOP vs OABI Comparison
Compare KNOP & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KNOP | OABI |
|---|---|---|
| Founded | 2013 | 2012 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 355.2M | 294.3M |
| IPO Year | 2012 | 2021 |
Fundamental Metrics
Financial Performance| Metric | KNOP | OABI |
|---|---|---|
| Price | $10.66 | $4.81 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | N/A | ★ $4.50 |
| AVG Volume (30 Days) | 38.4K | ★ 1.6M |
| Earning Date | 05-19-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.86% | N/A |
| EPS Growth | N/A | ★ 6.56 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $18,666,000.00 |
| Revenue This Year | $3.51 | $52.42 |
| Revenue Next Year | N/A | $64.69 |
| P/E Ratio | $9.00 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.45 | $1.32 |
| 52 Week High | $11.78 | $4.78 |
Technical Indicators
Market Signals| Indicator | KNOP | OABI |
|---|---|---|
| Relative Strength Index (RSI) | 51.25 | 89.53 |
| Support Level | $10.52 | $1.69 |
| Resistance Level | $10.82 | N/A |
| Average True Range (ATR) | 0.28 | 0.36 |
| MACD | 0.01 | 0.15 |
| Stochastic Oscillator | 42.86 | 99.18 |
Price Performance
Historical ComparisonAbout KNOP KNOT Offshore Partners LP
KNOT Offshore Partners LP owns, operates, and shuttles tankers under long-term charters in the North Sea and Brazil. The company provides crude oil loading, transportation, and storage services under time charters and bareboat charters. The Partnership is formed for acquiring ownership interests in over four shuttle tankers owned by Knutsen NYK Offshore Tankers AS (KNOT). It operates through the shuttle tanker market segment.
About OABI OmniAb Inc.
OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.